StreetInsider.com News Articles

Form 8-K BioRestorative Therapies For: May 26

Fri, 29 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260529/26576425.html

Form 8-K BioRestorative Therapies For: May 26

Fri, 29 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260529/26576425.html

Kaos Capital acquires 4.9% stake in BioRestorative Therapies

Wed, 27 May 2026 07:45:13 -0400

Kaos Capital Ltd., a Miami-based hedge fund, announced it acquired a 4.9% stake in BioRestorative Therapies Inc. (NASDAQ: BRTX) through open market purchases.

The activist investment firm said it seeks an immediate meeting with BRTX's board of directors to discuss strategic opportunities, including a potential pivot into artificial intelligence. Kaos Capital stated it believes the biotechnology company should explore a comprehensive strategic review.

"BRTX shareholders are not currently gaining meaningful value from the existing business," the hedge fund said in a statement. "We at Kaos feel that the Company should explore a comprehensive strategic review and consider a pivot into a broader

Kaos Capital acquires 4.9% stake in BioRestorative Therapies

Wed, 27 May 2026 07:45:13 -0400

Kaos Capital Ltd., a Miami-based hedge fund, announced it acquired a 4.9% stake in BioRestorative Therapies Inc. (NASDAQ: BRTX) through open market purchases.

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Wed, 27 May 2026 07:45:00 -0400

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders

MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").

This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Wed, 27 May 2026 07:45:00 -0400

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders

This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Wed, 27 May 2026 07:45:00 -0400

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders

This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Wed, 27 May 2026 07:45:00 -0400

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders

This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle

Form SCHEDULE 13G/A BioRestorative Therapies Filed by: Auctus Fund Management LLC

Fri, 15 May 2026 15:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26504276.html

Form SCHEDULE 13G/A BioRestorative Therapies Filed by: Auctus Fund Management LLC

Fri, 15 May 2026 15:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26504276.html

Form 10-Q BioRestorative Therapies For: Mar 31

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495777.html

Form 10-Q BioRestorative Therapies For: Mar 31

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495777.html

BioRestorative presents exosome data showing source-specific functions

Wed, 13 May 2026 11:00:17 -0400

BioRestorative Therapies Inc. (NASDAQ: BRTX) presented preclinical data at the International Society for Cell & Gene Therapy 2026 Annual Meeting showing that extracellular vesicles derived from different mesenchymal stem cell sources exhibit distinct protein signatures and biological functions.

The study, presented May 6 in Dublin, Ireland, analyzed extracellular vesicles from umbilical cord, brown adipose tissue, and bone marrow-derived mesenchymal stem cells. Proteomic analysis revealed source-specific functional pathways including proliferation and regenerative signaling, cell adhesion and immune modulation, and epidermal differentiation and barrier formation.

"These findings provide important insight into how we can tailor exosome-based formulations to achieve specific biological outcomes," said Francisco

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

Wed, 13 May 2026 11:00:00 -0400

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications

MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland. The data highlight the functional and proteomic differences of extracellular vesicles (“EVs”), including exosomes, derived from multiple mesenchymal stem cell

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

Wed, 13 May 2026 11:00:00 -0400

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications

Form 8-K BioRestorative Therapies For: May 01

Fri, 01 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260501/26417948.html

Form 8-K BioRestorative Therapies For: May 01

Fri, 01 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260501/26417948.html

Form 424B3 BioRestorative Therapies

Thu, 30 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260430/26408166.html

Form 424B3 BioRestorative Therapies

Thu, 30 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260430/26408166.html

BioRestorative Therapies to present clinical trial data at ISCT conference

Thu, 30 Apr 2026 10:36:16 -0400

BioRestorative Therapies Inc. (NASDAQ: BRTX) announced it will present data from its Phase 2 clinical trial and preclinical research at the International Society for Cell & Gene Therapy 2026 Annual Meeting in Dublin, Ireland from May 6-9.

The company will deliver two presentations at the conference. Francisco Silva, founder and chief scientist, will present safety and efficacy data from the company's Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease on May 6 at 9:15 AM. The trial is described as fully enrolled and ongoing.

Michael Joyce, director of research and development, will present preclinical data on the company's exosome

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

Thu, 30 Apr 2026 10:36:00 -0400

Data demonstrate progress in each of its MSC-derived programs

MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it will present new data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, taking place May 6-9 in Dublin, Ireland. The Company will have two presentations at the conference: safety and blinded efficacy data from its fully enrolled, ongoing Phase 2 clinical trial in chronic lumbar disc

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

Thu, 30 Apr 2026 10:36:00 -0400

Data demonstrate progress in each of its MSC-derived programs

Form EFFECT BioRestorative Therapies

Wed, 29 Apr 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260429/26387366.html

Form EFFECT BioRestorative Therapies

Wed, 29 Apr 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260429/26387366.html

Form POS AM BioRestorative Therapies

Mon, 27 Apr 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260427/26374663.html